Anti-B4-blocked ricin synergizes with doxorubicin and etoposide on multidrug-resistant and drug-sensitive tumors.

Anti-B4-blocked ricin (anti-B4-bR) is an immunotoxin directed against CD19-positive cells that is currently being tested in several B-cell leukemia/lymphoma clinical trials. To explore the possibility of using anti-B4-bR in combination with chemotherapy protocols, we investigated the in vitro and in vivo cytotoxic effects of combining it with doxorubicin or etoposide using the lymphoma cell line Namalwa and a P-glycoprotein-expressing cell line, Namalwa/mdr-1, obtained by retroviral infection of Namalwa cells with the mdr-1 gene. Namalwa/mdr-1 cells were slightly more sensitive to anti-B4-bR than Namalwa cells; IC37 values were approximately 4 pmol/L and 8 pmol/L, respectively. When anti-B4-bR was combined simultaneously with doxorubicin or etoposide, additive to supra-additive killing of Namalwa and Namalwa/mdr-1 cells was observed. In xenografts of Namalwa/mdr-1 cells in severe combined immunodeficiency (SCID) mice, doxorubicin and etoposide at their maximum tolerated doses (3 mg/kg x 3 or 15 mg/kg x 3) showed no therapeutic effect. However, treatment with 5 daily bolus injections of anti-B4-bR (50 micrograms/kg) followed by treatment with doxorubicin or etoposide significantly increased the life span of the mice by 129% and 115%, respectively. After treatment with anti-B4-bR, the Namalwa/mdr-1 population expressed lower levels of P-glycoprotein, and this decrease may account for the synergistic action of the drug combinations. These results suggest that anti-B4-bR could be used to good effect in combination with current treatment regimens and further hint at a promising role for this immunotoxin in treatment of disease at the minimal residual disease stage, where cells may be resistant to chemotherapy.

[1]  G. Mickisch.  Multidrug Resistance , 1996, Der Urologe A.

[2]  K. Tucker,et al.  Eradication of minimal disease in severe combined immunodeficient mice with disseminated Daudi lymphoma using chemotherapy and an immunotoxin cocktail. , 1994, Blood.

[3]  R. Bast,et al.  Alkylating agents and immunotoxins exert synergistic cytotoxic activity against ovarian cancer cells. Mechanism of action. , 1993, The Journal of clinical investigation.

[4]  R. Arceci.  Clinical significance of P-glycoprotein in multidrug resistance malignancies [editorial] [see comments] , 1993 .

[5]  O. Fardel,et al.  Expression of the multidrug resistance-associated P-glycoprotein (P-170) in 59 cases of de novo acute lymphoblastic leukemia: prognostic implications. , 1993, Blood.

[6]  J. Gribben,et al.  Adjuvant immunotoxin therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with B-cell non-Hodgkin's lymphoma. , 1993, Blood.

[7]  T M Grogan,et al.  Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.

[8]  S. Shah,et al.  Anti-B4-blocked ricin immunotoxin shows therapeutic efficacy in four different SCID mouse tumor models. , 1993, Cancer research.

[9]  F. Baas,et al.  Monoclonal antibody to an external epitope of the human mdr1 P-glycoprotein. , 1993, Cancer research.

[10]  L. Gordon,et al.  Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. , 1992, The New England journal of medicine.

[11]  B. Sikic,et al.  Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  B. Sikic,et al.  Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  B. Bierer,et al.  Immunosuppressants FK506 and rapamycin function as reversal agents of the multidrug resistance phenotype. , 1992, Blood.

[14]  Dorothea,et al.  Effective immunochemotherapy of CALLA+C mu+ human pre-B acute lymphoblastic leukemia in mice with severe combined immunodeficiency using B43 (anti-CD19) pokeweed antiviral protein immunotoxin plus cyclophosphamide. , 1992, Blood.

[15]  C. Coleman,et al.  Enhancement of alkylating agent activity by SR-4233 in the FSaIIC murine fibrosarcoma. , 1992, Journal of the National Cancer Institute.

[16]  J. Ritz,et al.  Serotherapy of B-cell neoplasms with anti-B4-blocked ricin: a phase I trial of daily bolus infusion , 1992 .

[17]  J. Ritz,et al.  Serotherapy of B-cell neoplasms with anti-B4-blocked ricin: a phase I trial of daily bolus infusion. , 1992, Blood.

[18]  L. Nadler,et al.  An immunotoxin prepared with blocked ricin: a natural plant toxin adapted for therapeutic use. , 1991, Cancer research.

[19]  M. Belvin,et al.  Anti-MY9-blocked-ricin: an immunotoxin for selective targeting of acute myeloid leukemia cells. , 1991, Blood.

[20]  W. Blättler,et al.  The galactose-binding sites of the cytotoxic lectin ricin can be chemically blocked in high yield with reactive ligands prepared by chemical modification of glycopeptides containing triantennary N-linked oligosaccharides. , 1991, Biochemistry.

[21]  L. Takemoto,et al.  Analysis of P-glycoprotein phosphorylation in HL60 cells isolated for resistance to vincristine. , 1991, The Journal of biological chemistry.

[22]  T. Miller,et al.  Systemic toxic effects associated with high-dose verapamil infusion and chemotherapy administration. , 1991, Journal of the National Cancer Institute.

[23]  V. Ling,et al.  P-glycoprotein expression in multidrug-resistant human ovarian carcinoma cell lines. , 1989, Cancer research.

[24]  M. Cairo,et al.  Clinical trial of continuous infusion verapamil, bolus vinblastine, and continuous infusion VP-16 in drug-resistant pediatric tumors. , 1989, Cancer research.

[25]  F. Baas,et al.  Genes amplified and overexpressed in human multidrug-resistant cell lines. , 1988, Cancer research.

[26]  R. Mulligan,et al.  Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[27]  D. Housman,et al.  Retroviral transfer of a murine cDNA for multidrug resistance confers pleiotropic drug resistance to cells without prior drug selection. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[28]  B. Teicher,et al.  Combination of N,N',N"-triethylenethiophosphoramide and cyclophosphamide in vitro and in vivo. , 1988, Cancer research.

[29]  D. Housman,et al.  Genetics of multidrug resistance: relationship of a cloned gene to the complete multidrug resistant phenotype. , 1987, Cancer research.

[30]  B. Chauffert,et al.  Amiodarone is more efficient than verapamil in reversing resistance to anthracyclines in tumour cells. , 1987, British Journal of Cancer.

[31]  I. Pastan,et al.  A monoclonal antibody-Pseudomonas toxin conjugate that specifically kills multidrug-resistant cells. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[32]  I. Pastan,et al.  Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[33]  J. Strominger,et al.  Expression of human class II major histocompatibility complex antigens using retrovirus vectors. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[34]  I. Pastan,et al.  Expression of a multidrug-resistance gene in human tumors and tissues. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[35]  D. Housman,et al.  Isolation and expression of a complementary DNA that confers multidrug resistance , 1986, Nature.

[36]  S. Gupta,et al.  Cyclosporin A reverses vincristine and daunorubicin resistance in acute lymphatic leukemia in vitro. , 1986, The Journal of clinical investigation.

[37]  T. Tsuruo,et al.  Effects of quinidine and related compounds on cytotoxicity and cellular accumulation of vincristine and adriamycin in drug-resistant tumor cells. , 1984, Cancer research.

[38]  G. Church,et al.  Genomic sequencing. , 1993, Methods in molecular biology.

[39]  A. Feinberg,et al.  "A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity". Addendum. , 1984, Analytical biochemistry.

[40]  J. Riordan,et al.  Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. , 1983, Science.

[41]  A. Feinberg,et al.  A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. , 1983, Analytical biochemistry.

[42]  T. Tsuruo,et al.  Increased accumulation of vincristine and adriamycin in drug-resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors. , 1982, Cancer research.